Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Efficacy of fixed low‐dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris

Efficacy of fixed low‐dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in... Background In view of the potentially serious side‐effects of standard isotretinoin (0.5–1.0 mg/kg per day) therapy for acne, we studied the safety and efficacy of low‐fixed dose isotretinoin plus topical 1%clindamycin gel in the treatment of moderate grade of acne. Methods In this prospective, non‐comparative study, 320 adult patients, with moderately severe acne were enrolled and treated with fixed‐dose isotretinoin at 20 mg every alternate day (approximately 0.15 mg/kg/day to 0.28 mg/kg/day) for 6 months along with topical clindamycin gel. All female patients were assessed for polycystic ovarian disease. Patients were followed up for 6 months. Results A total of 305 patients completed the study. Overall, patients received a mean of 38.4 mg/kg cumulative dose of isotretinoin, and very good results were observed in 208 (68.20%), while good response was seen in 59 (19.34%) of patients. Failure of the treatment occurred in 38 (12.46%), while relapses occurred in 50 (16.39%) of patients. Relapses were commoner in females, and 37 of 43 (86.04%) patients had polycystic ovarian disease. Though mild chelitis (91%) and xerosis (43%) were common, laboratory abnormalities in the form of elevated hepatic enzymes (5%) and elevated serum lipids (6%) were rare. Conclusion Six months of treatment with fixed‐dose, alternate‐day isotretinoin (20 mg) plus topical 1%clindamycin gel was found to be effective in the treatment of moderate acne in adult patients, with a low incidence of side‐effects. Conflicts of interest None declared http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Efficacy of fixed low‐dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris

Download PDF
5 pages

Loading next page...
 
/lp/wiley/efficacy-of-fixed-low-dose-isotretinoin-20-mg-alternate-days-with-UfNnuLlt1f

References (20)

Publisher
Wiley
Copyright
© 2009 The Authors. Journal compilation © 2009 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
DOI
10.1111/j.1468-3083.2008.03022.x
pmid
19143903
Publisher site
See Article on Publisher Site

Abstract

Background In view of the potentially serious side‐effects of standard isotretinoin (0.5–1.0 mg/kg per day) therapy for acne, we studied the safety and efficacy of low‐fixed dose isotretinoin plus topical 1%clindamycin gel in the treatment of moderate grade of acne. Methods In this prospective, non‐comparative study, 320 adult patients, with moderately severe acne were enrolled and treated with fixed‐dose isotretinoin at 20 mg every alternate day (approximately 0.15 mg/kg/day to 0.28 mg/kg/day) for 6 months along with topical clindamycin gel. All female patients were assessed for polycystic ovarian disease. Patients were followed up for 6 months. Results A total of 305 patients completed the study. Overall, patients received a mean of 38.4 mg/kg cumulative dose of isotretinoin, and very good results were observed in 208 (68.20%), while good response was seen in 59 (19.34%) of patients. Failure of the treatment occurred in 38 (12.46%), while relapses occurred in 50 (16.39%) of patients. Relapses were commoner in females, and 37 of 43 (86.04%) patients had polycystic ovarian disease. Though mild chelitis (91%) and xerosis (43%) were common, laboratory abnormalities in the form of elevated hepatic enzymes (5%) and elevated serum lipids (6%) were rare. Conclusion Six months of treatment with fixed‐dose, alternate‐day isotretinoin (20 mg) plus topical 1%clindamycin gel was found to be effective in the treatment of moderate acne in adult patients, with a low incidence of side‐effects. Conflicts of interest None declared

Journal

Journal of the European Academy of Dermatology & Venereology – Wiley

Published: May 1, 2009

There are no references for this article.